11-16-15 $CTIX ~ Cellceutix Corp. Due Diligence Report

New Post Public Reply Private Reply Replies (0) Message Board
TheHound
11-16-15 $CTIX ~ Cellceutix Corp. Due Diligence Report




$CTIX recent news


Press releases from Cellceutix:

http://cellceutix.com/category/press-release/...r967e.dpbs


PR's from Yahoo:

Mon, 16 Nov 2015 12:30:00 GMT ~ Cellceutix Selects Docetaxel for Combination Arm in Planned Phase 2 Trial for Ovarian Cancer

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, today reports that, based ...

read full: http://finance.yahoo.com/news/cellceutix-sele...00636.html

Wed, 11 Nov 2015 15:34:21 GMT ~ Cellceutix Completes Cohort in Kevetrin Clinical Trial; Cheers to Ocata Therapeutics

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to report that ...

read full: http://finance.yahoo.com/news/cellceutix-comp...21863.html


Tue, 10 Nov 2015 15:51:02 GMT ~ Cellceutix Files Form 10-Q for Quarter Ended September 30, 2015

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, has filed its quarterly report ...

read full: http://finance.yahoo.com/news/cellceutix-file...02882.html


Mon, 09 Nov 2015 21:13:18 GMT ~ CELLCEUTIX CORP Files SEC form 10-Q, Quarterly Report

read full: http://biz.yahoo.com/e/151109/ctix10-q.html


Tue, 03 Nov 2015 22:26:56 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statem

read full: http://biz.yahoo.com/e/151103/ctix8-k.html


Fri, 30 Oct 2015 17:00:10 GMT ~ Cellceutix aims for late-stage trial of antibiotic next year

read full: http://www.bizjournals.com/boston/blog/biofla...?ana=yahoo


Fri, 30 Oct 2015 12:17:00 GMT ~ How it All Plays Out - Research on Arena Pharmaceuticals, XOMA, Ekso Bionics and Cellceutix

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 30, 2015 / Moments ago, Trader's Choice released another issue of its world-class newsletter in which it took the time to review and explain some of the most talked ...

read full: http://finance.yahoo.com/news/plays-research-...00619.html


Fri, 30 Oct 2015 11:30:00 GMT ~ Cellceutix Provides Brilacidin Update; New Class of Antibiotics to Enter Phase 3

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to provide an update ...

read full: http://finance.yahoo.com/news/cellceutix-prov...00865.html


Mon, 26 Oct 2015 12:34:00 GMT ~ Cellceutix Due Diligence Report: False Accusations Cause Mayhem; Share Price Ready to Bounce

[Accesswire] - NEW YORK, NY / ACCESSWIRE / October 26, 2015 / Cellceutix Corp. (OTCMKTS: CTIX) a clinical stage biopharmaceutical company located in Beverly, Massachusetts developing innovative therapies in oncology, ...

read full: http://finance.yahoo.com/news/cellceutix-due-...00041.html


Mon, 26 Oct 2015 11:40:04 GMT ~ Cellceutix to Request Meeting With FDA for Phase 2 Ovarian Cancer Study; Company's First-in-Human Study Defines the Pharmacokinetic Profile of Kevetrin

[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic applications, is pleased to inform shareholders ...

read full: http://finance.yahoo.com/news/cellceutix-requ...04556.html


Thu, 22 Oct 2015 18:28:15 GMT ~ Cellceutix Responds to Rosen Law Firm

[Marketwired] - Cellceutix Corporation , Cellceutix was created to tackle some of the worst diseases known to man. We are a company that firmly believes in the strength of our science and technology. It is our science ...

read full: http://finance.yahoo.com/news/cellceutix-resp...15404.html


$CTIX filings - Perhaps the most important section.

http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany



basic chart ## source: stockscores.com





$CTIX company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTC Pink Current
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA

## source: Opinion summary from various sources.

Additional $CTIX company information:

Business Description: Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix’s anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. This trial just completed its final cohort. Plans for a Ph 2/3 Ovarian Cancer Study are underway. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the “Guardian Angel Gene” due to its crucial role in controlling cell mutations. Cellceutix is currently conducting a Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix’s anti-psoriasis drug Prurisol is presently in Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix’s key antibiotic, Brilacidin, recently completed a successful Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Plans for a phase 3 trial are underway w/ FDA's approval. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. Please click on the below link to find for more information on completed and active Human Clinical Trials.


https://www.clinicaltrials.gov/ct2/results?te...rch=Search




$CTIX share structure

## source: otcmarkets.com

Market Value: $153,621,697 a/o Nov 10, 2015
Shares Outstanding: 118,170,536 a/o Aug 26, 2015
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
Par Value: 0.0001



$CTIX extra dd links

Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com

## STOCK DETAILS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CTIX+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CTIX+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CTIX+Industry

## COMPANY NEWS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/news - http://finance.yahoo.com/q/h?s=CTIX+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CTIX/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CTIX+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CTIX
DTCC (dtcc.com): http://search2.dtcc.com/?q=Cellceutix+Corp.&a...ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&am...eutix+Corp.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results...=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cellceutix.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cellceutix.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cellceutix.com

## FUNDAMENTALS ##
Clinical Trials:
https://clinicaltrials.gov/ct2/results?term=c...rch=Search
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/compa...yword/CTIX
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/financials?...-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?...rch=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CTIX
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CTIX+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CTIX+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CTIX
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CTIX
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CTIX+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CTIX/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CTIX+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CTIX.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CTIX
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CTIX/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CTIX/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CTIX
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CTIX
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CTIX:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CTIX
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/st...icker=CTIX



1) UPCOMING MILESTONES / CATALYSTS

SCIENCE:

- Start of B-ABSSSI (Phase 3) (With Fast-Track designation, per QIDP)
- Completion of K (Phase 1) (more dets as to safety, efficacy)
- Initiation of several K phase 2, 2/3 trials (ovarian, pancreatic, AML) (more frequent dosing likely, grant support--addtl Orphan designation/s)
- Meeting w / FDA on K-pediatric retinoblastoma (rare disease)
- Phase 2 B-OM update
- Phase 2 P update/completion
- ABX platform -- progress on anti-fungals, anti-biofilm (MTA signed for B-prophylactic testing), gram-neg compounds; GI targets (Chrons, IBD, H Supportiva)

OPERATIONS:

- Financing in place (shelf, Aspire)
- 1st Shareholder meeting (Dec 15... Be it pitchfork or rose petal in feel)
- NASDAQ uplisting (if $2 is maintained)
- Class Action Defense (Legal)
- Partners: still think this is likely farther off... Post Ph III ABSSSI for ABX... And will it be by indication or for whole platform? Kevetrin, the wildcard... As a case study, see CELG-Nurix deal (p53)

https://blogs.shu.edu/cancer/2015/09/30/ubiqu...d-celgene/

2) CURRENT TRIALS:

Clinical Trials

Overall - https://clinicaltrials.gov/ct2/results?term=c...rch=Search

1. P (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=1

2. B-OM (Phase 2, recruiting): https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3

3. K (Phase 1, Not recruiting): https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=4

4. B-ABSSSI (Phase 2, completed): https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=5

Abbreviations:

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP – qualified infectious disease product

Company Website:
http://www.cellceutix.com

**This section courtesy of Slcimmuno - Thanks brother!**

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

4Roots Picks MSG for IT & Cybersecurity Support

Updated Category News Views 0

Tech-Boost for a Community Farm Vision Seems like everyone's buzzing about sustainability these days, and why not? It's the way forward. Take 4Roots and their Farm Campus initiative in Orlando. They've hooked up with Managed Services Group (MSG) to bolster their tech backbone, raising the stakes for their mission to shake up the food system. It's a no-nonsense...

Continue Reading
Potassium Fluoride Market Growth Sparks Interest

Updated Category News Views 2

Here's a story you might not have expected—potassium fluoride is finding its spotlight! With the market projected to tick upwards from USD 0.43 billion in 2026 to USD 0.51 billion by 2032, there's more here than meets the eye. A steady CAGR of 2.9% might not scream excitement, but steady growth often does the trick in chemicals. Why the Buzz Around Potassium Fluoride?...

Continue Reading
FirstEnergy's Bold Move: Dormo Joins to Boost Power

Updated Category News Views 1

Changing the Game in Power Generation In the ever-shifting landscape of power generation, having a seasoned player at the helm can be the difference between stagnation and growth. FirstEnergy Corp. (NYSE:FE) has tapped Jon Dormo as its Vice President of Generation Project Development. The mission? Overhaul and expand projects to meet the increasing demands for...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 2

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
Cypress Wood's Resilience in Louisiana's Humidity

Updated Category News Views 1

Timber Talk with Wes McAdams Diving into the nitty-gritty of building materials isn't everyone's cup of tea, but when you live in a place like Baton Rouge, understanding what stands up to the swampy summer heat is plain survival. The main focus? Cypress wood. Now, Wes McAdams from Cajun Cypress throws his hat into the ring, shedding some light on why cypress might just be...

Continue Reading
Hamamatsu & AIxMed to Automate Cytology Workflows

Updated Category News Views 2

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...

Continue Reading
Truist Revolutionizes Banking with 2 Billion Insights

Updated Category News Views 1

A New Frontier in Banking Truist is out here flipping the script in digital banking, pushing a staggering 2 billion AI-driven insights since 2023. Imagine that—two billion insights 'till now, providing the kind of financial street smarts that help folks feel less like they're lost at sea and more like they're the captain of their own financial ship, all thanks to Truist...

Continue Reading
Herzog Joins Greenberg Traurig: A Litigation Powerhouse

Updated Category News Views 5

Greenberg Traurig Welcomes David M. Herzog to the Team Ah, the rat race of litigation just got a bit fiercer with Greenberg Traurig's latest acquisition: David M. Herzog. This isn’t just another lawyer joining the ranks; Herzog's a dynamo, coming in hot from the U.S. Attorney's Office, right onto the battlefield of corporate litigation. Why Herzog's Move Matters...

Continue Reading
Courtesy Auto Group Expands with Tucson Dealerships Buy

Updated Category News Views 4

Moving Pieces in the Automotive Puzzle Here's one for the books, folks. Automotive dealership chessboard gets another shuffle. Scott Gruwell, the big wheel behind Courtesy Automotive Group, has snatched up Watson Chevrolet and Infiniti of Tucson. Just one more notch in someone's power belt—operations now rolling under new banners as Courtesy Chevrolet and Courtesy...

Continue Reading
Zum Drivers Shine as New School Year Begins

Updated Category News Views 2

Opening the School Year with High Hopes Zum's crew of enthusiastic drivers hit the streets with a mission: kickstarting the new school year with a sense of excitement that feels fresh, even to a grizzled trader like me. These folks are doing more than just turning the ignition, they’re handling a vital cog in the education machine. From Fresno down to Rockford, you’ll...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Exempt Principal Trader Dealings in FD Technologies

Updated Category News Views 223

Key Insights on Public Offering Rule 8.5 In the dynamic landscape of finance, transparency is critical, especially regarding trading activities involving exempt principal traders. FD Technologies plc, in compliance with Rule 8.5 of the Takeover Code, has made a significant public disclosure. This regulation emphasizes the necessity for principal traders to maintain an...

Continue Reading
ZenaTech's ZenaDrone Aims for FAA Certification in Agriculture

Updated Category News Views 161

ZenaTech's Ambitious Step Towards FAA Certification In an exciting development for the agricultural technology sector, ZenaTech, Inc. (Nasdaq: ZENA) has taken significant strides with its innovative ZenaDrone 1000. The company has recently applied for the Federal Aviation Authority (FAA) Part 137 certification to utilize its drone in crop spraying applications. This...

Continue Reading
Innovative Lithium Safety Solutions: FCL-X™ Live Showcase

Updated Category News Views 135

Full Circle Lithium and the FCL-X™ Introduction Full Circle Lithium Corp. (TSXV: FCLI, OTCQB: FCLIF) is preparing to present its groundbreaking lithium battery extinguishing solution, the FCL-X™, at the LithiumSAFE Battery Safety Workshop Conference. This much-anticipated event will highlight FCL's commitment to enhancing safety measures in the lithium battery...

Continue Reading
BrainStorm Cell Therapeutics Reports Q3 Financials and Updates

Updated Category News Views 108

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent developer of adult stem cell therapeutics for neurodegenerative disorders, has disclosed its financial outcomes for the third quarter. The company continues to advance its innovative NurOwn program aimed at providing therapeutic...

Continue Reading
Sweet Paris Crêperie Expands with New Franchises in the Midwest

Updated Category News Views 202

Sweet Paris Crêperie Expands into the Midwest Sweet Paris Crêperie & Café, a beloved restaurant brand known for its mouthwatering crêpes and inviting atmosphere, is set to broaden its horizons with exciting plans for expansion into two new states. This ambitious move will see the opening of four new locations in Arkansas and Missouri, enhancing the restaurant's...

Continue Reading